EGFR-TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation.
about
Factors that predict progression-free survival in Chinese lung adenocarcinoma patients treated with epidermal growth factor receptor tyrosine kinase inhibitorsIs there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in ALK-positive advanced lung adenocarcinoma? A retrospective study of Chinese patients.Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma.The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.The safety of afatinib for the treatment of non-small cell lung cancer.Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.Survival analysis of patients with advanced non-small cell lung cancer receiving tyrosine kinase inhibitor (TKI) treatment: A multi-center retrospective study.Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma.Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis.Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non-small cell lung cancer: a meta-analysis
P2860
Q36540405-65C9816C-A03F-4D76-AB01-394A1B5D1EABQ37045504-DCA931A1-851E-4F1A-B693-2B489181F9B6Q37697247-7054CF0F-D68C-4DB8-BA58-CD5DFCD5CADEQ37709481-F23E4FBA-CB01-4CB7-A848-1BEC255512A9Q38955468-429BCAF6-51AE-4AB0-A072-339974F52083Q39179464-A8E3DB47-A3AE-4EF4-966B-6BC9739A0E81Q48365834-2BCF9173-1D0D-4107-842A-1DCADB1B066FQ53394177-56742E7B-0DE6-4ED1-A56B-CAF767720D0BQ54115504-BF67007A-59D6-465C-BC1D-AAC2F98FDC36Q58803156-79F1AF17-0C0E-4277-9908-B36658802A0B
P2860
EGFR-TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
EGFR-TKI is effective regardle ...... ocarcinoma with EGFR mutation.
@en
EGFR-TKI is effective regardle ...... ocarcinoma with EGFR mutation.
@nl
type
label
EGFR-TKI is effective regardle ...... ocarcinoma with EGFR mutation.
@en
EGFR-TKI is effective regardle ...... ocarcinoma with EGFR mutation.
@nl
prefLabel
EGFR-TKI is effective regardle ...... ocarcinoma with EGFR mutation.
@en
EGFR-TKI is effective regardle ...... ocarcinoma with EGFR mutation.
@nl
P2093
P2860
P1476
EGFR-TKI is effective regardle ...... ocarcinoma with EGFR mutation.
@en
P2093
Chang-Min Choi
Dae-Ho Lee
Jae Cheol Lee
Jung-Shin Lee
Kyu-pyo Kim
Sang-We Kim
Se Jin Jang
P2860
P2888
P304
P356
10.1007/S00280-014-2631-5
P50
P577
2014-11-25T00:00:00Z